Mirikizumab

SAN FRANCISCO — Most patients with moderately to severely active Crohn’s disease who achieved endoscopic response and remission after 52 weeks of Omvoh therapy maintained those results through 104 weeks, according to VIVID-2 study results.

In this Healio video, Uma Mahadevan, MD, director of the Colitis and Crohn’s Disease Center at the University of California, San Francisco, discusses new study results assessing the use of interleukin-23 inhibitors in ulcerative colitis.

WASHINGTON — In this video, Mark Genovese, MD, discusses results of the VIVID-1 study, in which mirikizumab demonstrated noninferiority to ustekinumab for week 52 clinical remission among patients with moderate to severe Crohn’s disease.

LAS VEGAS —A presenter at the Crohn’s & Colitis Congress outlined some of the newer therapies that have expanded the current “arsenal of tools” for the treatment of inflammatory bowel disease.

Adam S. Cheifetz, MD, director of the Center for Inflammatory Bowel Disease, medical director of Infusion Services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, spoke with Healio about ulcerative colitis.

Adam S. Cheifetz, MD, director of the Center for Inflammatory Bowel Disease, medical director of Infusion Services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, spoke with Healio about ulcerative colitis.

Adam S. Cheifetz, MD, director of the Center for Inflammatory Bowel Disease, medical director of Infusion Services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, spoke with Healio about ulcerative colitis.

Adam S. Cheifetz, MD, director of the Center for Inflammatory Bowel Disease, medical director of Infusion Services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, spoke with Healio about ulcerative colitis.

Adam S. Cheifetz, MD, director of the Center for Inflammatory Bowel Disease, medical director of Infusion Services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, spoke with Healio about ulcerative colitis.

The FDA has approved Eli Lilly’s Omvoh infusion/injection as the “first and only” interleukin-23p19 antagonist for the treatment of patients with moderately to severely active ulcerative colitis, according to a company release.